2020
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma
Bonazzoli E, Bellone S, Zammataro L, Gnutti B, Guglielmi A, Pelligra S, Nagarkatti N, Manara P, Tymon-Rosario J, Zeybek B, Altwerger G, Menderes G, Han C, Ratner E, Silasi DA, Huang GS, Andikyan V, Azodi M, Schwartz PE, Santin AD. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma. Gynecologic Oncology 2020, 158: 769-775. PMID: 32600791, PMCID: PMC8253557, DOI: 10.1016/j.ygyno.2020.06.484.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsCell Line, TumorFemaleHumansImidazolesIn Situ Hybridization, FluorescenceIsoxazolesMiceMiddle AgedProteinsProto-Oncogene Proteins c-mycSignal TransductionTumor Suppressor ProteinsUbiquitin-Protein LigasesUterine Cervical NeoplasmsXenograft Model Antitumor AssaysYoung AdultConceptsC-myc expressionC-Myc pathwayTwice-daily oral dosesC-MycWestern blotChemotherapy-resistant diseaseUterine cervical carcinomaPotential therapeutic targetEffective therapeutic agentDose-response decreaseCC xenograftsCell line growthOral dosesCervical carcinomaPrimary tumorDeletion/mutationClinical studiesTherapeutic targetTherapeutic agentsNormal tissuesBET inhibitorsVivo activityQRT-PCRCell proliferationGene deletion/mutation
2015
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Kumara H, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden M, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars In Cancer Biology 2015, 35: s276-s304. PMID: 26590477, PMCID: PMC4819002, DOI: 10.1016/j.semcancer.2015.09.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds
Amin ARMR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, Shin DM. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars In Cancer Biology 2015, 35: s55-s77. PMID: 25749195, PMCID: PMC4561219, DOI: 10.1016/j.semcancer.2015.02.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsCarcinogenesisCell ProliferationDNA-Binding ProteinsGrowth Differentiation Factor 15Hippo Signaling PathwayHumansKruppel-Like Transcription FactorsMolecular Targeted TherapyNeoplasmsNuclear ProteinsProtein Serine-Threonine KinasesPTEN PhosphohydrolaseRetinoblastoma ProteinSignal TransductionSomatomedinsTranscription FactorsTumor Suppressor Protein p53ConceptsInsulin-like growth factorGrowth signalingCancer cellsGrowth differentiation factor 15Cell growthSuppression of genesActivation of genesDifferentiation factor 15AT-rich interactive domain 1ASignaling processesRetinoblastoma proteinFactor 15Tensin homologRb pathwayClinical settingSignalingGrowth factorAdverse effectsDomain 1AMolecular targetsPotential targetPathwayHippoGenesImportant pathwayIGF2 signaling and regulation in cancer
Brouwer-Visser J, Huang GS. IGF2 signaling and regulation in cancer. Cytokine & Growth Factor Reviews 2015, 26: 371-377. PMID: 25704323, DOI: 10.1016/j.cytogfr.2015.01.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2014
Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer
Brouwer-Visser J, Lee J, McCullagh K, Cossio MJ, Wang Y, Huang GS. Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer. PLOS ONE 2014, 9: e100165. PMID: 24932685, PMCID: PMC4059749, DOI: 10.1371/journal.pone.0100165.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, PhytogenicApoptosisBlotting, WesternCell CycleCell ProliferationCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiceMice, NudeOvarian NeoplasmsPaclitaxelPhosphorylationReal-Time Polymerase Chain ReactionReceptor, IGF Type 1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, Small InterferingSignal TransductionTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsDrug-resistant ovarian cancerResistant ovarian cancerInsulin-like growth factorIGF2 knockdownOvarian cancerPotential therapeutic targetDrug resistanceTherapeutic targetCell linesOvarian cancer xenograft modelDrug-sensitive cell linesOvarian cancer cohortTaxol sensitivityOvarian cancer cell linesCancer xenograft modelExtreme drug resistanceDose of TaxolDrug-resistant cellsCancer Genome Atlas (TCGA) dataNovel potential targetSensitive cell linesCancer cell linesShort hairpin RNAClinical indicatorsCancer cohort
2010
Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. Clinical Cancer Research 2010, 16: 2999-3010. PMID: 20404007, PMCID: PMC2887721, DOI: 10.1158/1078-0432.ccr-09-3233.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicBiomarkers, TumorCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansInsulin-Like Growth Factor IIOvarian NeoplasmsPaclitaxelPhosphorylationPrognosisProto-Oncogene Proteins c-aktPyrimidinesPyrrolesReceptor, IGF Type 1RNA, Small InterferingSignal TransductionConceptsEpithelial ovarian tumorsInsulin-like growth factorDisease-free survivalOvarian carcinoma cellsOvarian tumorsTaxol resistancePathway inhibitionIGF2 expressionOvarian cancerCarcinoma cellsExact testReduced disease-free survivalHuman epithelial ovarian tumorsCandidate prognostic biomarkerDrug-resistant ovarian carcinoma cellsUpregulation of IGF2Fisher's exact testIGF2 protein expressionOvarian cancer cellsDrug-resistant phenotypeHigh IGF2 expressionIGF receptor inhibitorsPathologic factorsTaxol-resistant cell linesCox regression
2009
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma
Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, Goldberg GL. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. American Journal Of Obstetrics And Gynecology 2009, 200: 457.e1-457.e5. PMID: 19200930, PMCID: PMC2676778, DOI: 10.1016/j.ajog.2008.12.012.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionEstrogen receptor beta expressionGrowth factor receptor expressionEstrogen receptor betaReceptor 2 expressionDisease progressionReceptor expressionEstrogen receptor alphaFactor receptor expressionNormal endometriumUterine carcinosarcomaBeta expressionReceptor alphaReceptor betaHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Insulin-like growth factor receptor expressionAdvanced stage diseaseGrowth factor receptor 2Progesterone receptor expressionInsulin-like growth factor receptorTissue microarray analysisFactor receptor 2Wilcoxon rank sum test